Infections

All Conditions

Neoplasms

Blood and Lymph Conditions

Immune System Diseases

Symptoms and General Pathology

Rare Diseases

Leukemia

Leukemia, Lymphoid

Communicable Diseases

Leukemia, Lymphocytic, Chronic, B-Cell

Agammaglobulinemia

Neoplasms by Histologic Type

Hematologic Diseases

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Leukemia, B-Cell

Chronic Disease

Disease Attributes

Blood Protein Disorders

Syndrome

Immunologic Deficiency Syndromes

Chronic Graft Versus Host Disease

Chronic Lymphocytic Leukemia

Panzyga is a 10% IVIG produced from a pool of human fresh frozen plasma donations

Panzyga

Placebo

Patrick M Murphy

Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients with Chronic Lymphocytic Leukemia

Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)

Major infection for this trial is defined as:

* Bacterial and/or viral infections resulting in death
* Bacterial and/or viral infections, which are microbiologically documented (MDI) or clinically documented (CDI) requiring treatment with anti-infectives; upper respiratory tract infections, bronchitis, lower urinary tract infections, localized skin infections and stomatitis (MDI or CDI) are considered major only if they require treatment with antiinfectives AND hospitalization or hospitalization prolongation.
* Fever of unknown origin (FUO) requiring hospitalization or hospitalization prolongation

Inclusive of antibacterials and antivirals

Octapharma

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)	NCT04502030	Chronic Lymphoc... Hypogammaglobul...	Panzyga Placebo	18 Years -	Octapharma
Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)	NCT04502030	Chronic Lymphoc... Hypogammaglobul...	Panzyga Placebo	18 Years -	Octapharma

Spots Global Cancer Trial Database for panzyga

Every month we try and update this database with for panzyga cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for panzyga

Every month we try and update this database with for panzyga cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for panzyga cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.